With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Restoring RUNX1 Levels in FPD/AML||University of Washington, Seattle / Marshall Horwitz, MD/PhD||RARE Grant Program (Research Accelerating RUNX1 Exploration)||2016||Washington|
|Resistance and Develop Improved Treatments for Relapsed/refractory Pediatric ALL||Dana-Farber Cancer Institute / Elizabeth Townsend, PhD||Young Investigator Grants||2016||Massachusetts|
|Redefining the Cellular Architecture of Diffuse Intrinsic Pontine Glioma through Large-Scale Single-cell RNA-seq Analyses||Massachusetts General Hospital / Mario Suva, MD/PhD||Innovation Grants||2016||Massachusetts|
|Preclinical Testing of Candidate Therapeutics in a Pediatric Spinal Cord High-grade Glioma Model||Stanford University / Michelle Monje, MD/PhD||Innovation Grants||2016||California|
|Pre-clinical Testing of Novel Glutamine Metabolic Inhibitors in MYC-driven Medulloblastoma||The Johns Hopkins University School of Medicine / Eric Raabe, MD/PhD & Dr. Barbara Slusher, PhD||Innovation Grants||2016||Maryland|
|Pre-clinical Evaluation of LSD1 Inhibitors for the Treatment of Pediatric Ewing sarcoma: Defining the Biomarkers of Sensitivity and Mechanisms of Resistance||Research Institute at Nationwide Children's Hospital / Kathleen Pishas, PhD||Young Investigator Grants||2016||Ohio|
|Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML||Boston Children’s Hospital / Alan Cantor, MD, PhD||RARE Grant Program (Research Accelerating RUNX1 Exploration)||2016||Massachusetts|
|Neurocognitive Outcomes in Survivors of Childhood Leukemia with Down Syndrome||St. Jude Children’s Research Hospital / Lisa Jacola, PhD||Psychosocial Grants||2016||Tennessee|
|MYC as a Driver and Anti-Cancer Target in Malignant Rhabdoid Tumors||Vanderbilt University Medical Center / William Tansey, PhD||Innovation Grants||2016||Tennessee|
|Molecular Basis of ALK Inhibition Resistance in High-risk Neuroblastoma||Dana-Farber Cancer Institute / David Debruyne, PhD||Young Investigator Grants||2016||Massachusetts|